Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by Two Sigma Investments LP

Two Sigma Investments LP lifted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 80.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,884 shares of the company's stock after purchasing an additional 80,417 shares during the period. Two Sigma Investments LP owned about 0.12% of Denali Therapeutics worth $3,666,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of DNLI. Rhumbline Advisers grew its position in shares of Denali Therapeutics by 0.3% in the fourth quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock valued at $3,880,000 after purchasing an additional 497 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after purchasing an additional 885 shares during the period. Sterling Capital Management LLC grew its position in shares of Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Denali Therapeutics by 0.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 208,521 shares of the company's stock valued at $4,250,000 after purchasing an additional 1,702 shares during the period. Finally, E Fund Management Co. Ltd. grew its position in shares of Denali Therapeutics by 32.2% in the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Stock Performance

Shares of NASDAQ:DNLI traded up $0.72 during midday trading on Monday, hitting $13.96. 2,561,972 shares of the company's stock traded hands, compared to its average volume of 1,116,092. The company has a market cap of $2.03 billion, a PE ratio of -5.06 and a beta of 1.49. The firm's fifty day moving average price is $13.84 and its two-hundred day moving average price is $18.38. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter last year, the business posted ($0.68) EPS. As a group, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. William Blair raised Denali Therapeutics to a "strong-buy" rating in a research report on Thursday, April 24th. Oppenheimer lowered their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. B. Riley reissued a "buy" rating and set a $35.00 price objective (down from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Morgan Stanley initiated coverage on shares of Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 price objective for the company. Finally, Bank of America lowered their price objective on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a research note on Monday, May 19th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of "Buy" and an average price target of $33.71.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.